The Interreg ALCOVE project team sends you its warmest wishes for the year ahead.
Our engineering teams, technicians and technical staff achieved major progress in designing, miniaturising, and assembling the sensors, resulting in the production of 11 electronic nose prototypes (V1 version) — the technological core of the project.
We would also like to extend our sincere thanks to the clinical teams, who carried out essential preparatory work — administrative, organisational and logistical — to make the upcoming clinical study possible.
2026 will mark a decisive turning point with the launch of the first ALCOVE clinical study
The study will be deployed across 9 centres in the cross‑border region:
5 centres in Belgium
4 centres in France
This study, entitled “Development of a discrimination algorithm to assess e‑nose ability to separate lung cancer (LC) patients vs. non‑LC subjects”, aims to expose the still “naive” V1 prototypes to two populations:
individuals without pathology,
patients with resectable or non‑resectable lung cancer.
The goal is to develop and train a discrimination algorithm capable of identifying the resistance profiles specific to each group.
Primary endpoint of the study
To assess the ability of the electronic nose — and therefore the algorithm — to distinguish lung cancer cases from the non‑LC population.
The target accuracy is 80% (± 5%), with a minimum expected performance of > >75% to validate the primary objective.
An ambitious scientific challenge, made possible through close cooperation between French and Belgian partners.
The ALCOVE project warmly thanks the Interreg France–Wallonie–Vlaanderen programme, whose support allows us to advance research for the benefit of populations across the France–Belgium cross‑border region.
Together, let’s make 2026 a decisive year for health‑driven innovation.
Happy New Year 2026!
